US stock insider trading | Immunome disclosed two insider transactions on March 12.

K-LinePoet · 2026-04-06T13:47:21+00:00

Immunome disclosed insider trading on March 12, 2026. Director BIENAIME JEAN JACQUES bought 1,000 shares on March 10 and 11, respectively, with a total transaction amount of approximately $43.7k. Immunome is a biotechnology company focused on the development of cancer therapies.

K-LinePoet

2026-04-06 13:47:21

Abstract generation in progress

On March 12, 2026, Immunome (IMNM) disclosed two company insider transactions. On March 11, 2026, Director BIENAIME JEAN JACQUES purchased 1,000 shares.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price Per Share/US$	Total Amount/US$
March 12, 2026	Director	BIENAIME JEAN JACQUES	March 10, 2026	Buy	1000	22.12	22.1k
March 12, 2026	Director	BIENAIME JEAN JACQUES	March 11, 2026	Buy	1000	21.55	21.6k
December 30, 2025	Director	SIEGALL CLAY B	December 30, 2025	Buy	4729	21.15	100.0k
December 23, 2025	Director	Barchas Isaac	December 22, 2025	Sell	371.9k	21.72	8.0787m
December 23, 2025	Director	Barchas Isaac	December 22, 2025	Sell	11.3k	22.34	251.3k
December 22, 2025	Executive	Tsai Philip	December 19, 2025	Buy	10k	20.49	204.9k
December 18, 2025	Director	SIEGALL CLAY B	December 18, 2025	Buy	46.5k	21.50	1M
September 11, 2025	Executive	Higgins Jack	September 10, 2025	Buy	22k	1.35	29.7k
June 3, 2025	Director	BIENAIME JEAN JACQUES	June 3, 2025	Buy	5000	9.38	46.9k
March 28, 2025	Executive	Higgins Jack	March 27, 2025	Buy	5200	1.35	7020.00

【Company Information】

Immunome, Inc. was incorporated in Pennsylvania on March 2, 2006, and on December 2, 2015, converted to a Delaware company. The company is a biotechnology firm focused on the development of targeted cancer therapies. Immunome is committed to building a diversified portfolio of differentiated clinical assets to improve the quality of life of cancer patients. The core of its strategy lies in its expertise in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other cancer therapies. Immunome is advancing an R&D pipeline that includes multiple clinical and preclinical assets, reflecting its commitment to innovation in the oncology space.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.